Index
RUT
P/E
-
EPS (ttm)
-2.31
Insider Own
9.48%
Shs Outstand
57.66M
Perf Week
-6.50%
Market Cap
1.64B
Forward P/E
-
EPS next Y
-0.69
Insider Trans
-3.90%
Shs Float
52.42M
Perf Month
-19.75%
Enterprise Value
1.38B
PEG
-
EPS next Q
-0.59
Inst Own
59.15%
Perf Quarter
-2.71%
Income
-114.59M
P/S
-
EPS this Y
73.89%
Inst Trans
24.71%
Perf Half Y
398.41%
Sales
0.00M
P/B
5.87
EPS next Y
-17.14%
ROA
-47.74%
Perf YTD
-1.73%
Book/sh
4.83
P/C
5.89
EPS next 5Y
-
ROE
-56.40%
52W High
40.37 -29.75%
Perf Year
157.58%
Cash/sh
4.81
P/FCF
-
EPS past 3/5Y
-24.12% -20.84%
ROIC
-39.16%
52W Low
4.30 559.53%
Perf 3Y
530.22%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
6.23% 6.35%
Perf 5Y
644.35%
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
-62.96%
Oper. Margin
-
ATR (14)
2.06
Perf 10Y
-13.35%
Dividend Ex-Date
-
Quick Ratio
8.42
Sales Y/Y TTM
-100.00%
Profit Margin
-
RSI (14)
40.55
Dividend Gr. 3/5Y
- -
Current Ratio
8.42
EPS Q/Q
-10.57%
SMA20
-10.81%
Beta
0.45
Payout
-
Debt/Eq
0.08
Sales Q/Q
-
SMA50
-10.86%
Rel Volume
0.74
Prev Close
26.92
Employees
231
LT Debt/Eq
0.05
SMA200
46.50%
Avg Volume
1.28M
Price
28.36
IPO
Jun 20, 2002
Option/Short
Yes / Yes
Trades
Volume
528,716
Change
5.35%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-30-25 Initiated Alliance Global Partners
Buy
$20
Jun-26-25 Initiated B. Riley Securities
Buy
$21
May-20-25 Initiated Roth Capital
Buy
$31
Oct-21-24 Initiated Piper Sandler
Overweight
$35
May-17-24 Initiated Oppenheimer
Outperform
$14
Jan-05-24 Initiated Cantor Fitzgerald
Overweight
$8
Oct-26-22 Initiated Ladenburg Thalmann
Buy
$15
Dec-26-18 Downgrade Maxim Group
Buy → Hold
Jan-26-18 Reiterated H.C. Wainwright
Buy
$6.50 → $8.60
Sep-15-17 Reiterated H.C. Wainwright
Buy
$2.15 → $6.50
Feb-13-17 Resumed Rodman & Renshaw
Buy
$14
Jul-06-16 Resumed H.C. Wainwright
Buy
$13
Jun-15-16 Initiated ROTH Capital
Buy
Show Previous Ratings
May-13-26 01:02AM
May-12-26 04:21PM
04:05PM
May-11-26 06:00AM
May-04-26 04:05PM
09:00AM
Loading…
Apr-22-26 09:00AM
Mar-25-26 07:30AM
Mar-23-26 10:50AM
Mar-12-26 11:07PM
04:27PM
(Associated Press Finance)
04:01PM
09:00AM
Mar-10-26 10:47AM
09:25AM
07:00AM
01:32PM
Loading…
Mar-09-26 01:32PM
01:15PM
(The Wall Street Journal)
08:30AM
Mar-03-26 05:30AM
(The Wall Street Journal)
Feb-24-26 09:00AM
Jan-21-26 10:49AM
Jan-20-26 09:15AM
Jan-09-26 06:01AM
Dec-18-25 01:14PM
Dec-16-25 04:05PM
Dec-05-25 10:34AM
06:15AM
Dec-04-25 04:01PM
Dec-03-25 01:03PM
(Investor's Business Daily)
+371.07%
10:36AM
07:20AM
Loading…
07:20AM
06:10AM
Nov-24-25 09:00AM
Nov-11-25 12:00AM
Nov-10-25 04:50PM
(Associated Press Finance)
-6.24%
04:01PM
Nov-04-25 06:05PM
Nov-03-25 09:15AM
Oct-31-25 09:15AM
Oct-30-25 09:23AM
Sep-26-25 06:45AM
Sep-25-25 07:15AM
06:50AM
Sep-10-25 07:43AM
(Pharmaceutical Technology)
Sep-09-25 09:20AM
Sep-02-25 03:40AM
Aug-28-25 04:21PM
Aug-25-25 09:22AM
Aug-21-25 04:20PM
Aug-18-25 09:00AM
08:28AM
Aug-15-25 09:15AM
Aug-14-25 04:26PM
Aug-12-25 09:30AM
03:05AM
Aug-11-25 06:06PM
(Associated Press Finance)
-13.84%
04:05PM
11:01AM
06:22AM
Aug-08-25 08:30AM
Aug-07-25 06:35PM
Aug-06-25 09:00AM
Aug-05-25 10:45AM
Jul-29-25 08:23AM
Jul-28-25 09:00AM
Jul-25-25 08:07AM
Jul-22-25 04:26PM
10:05AM
Jul-21-25 04:46PM
Jul-14-25 11:33AM
Jul-11-25 10:50AM
(Investor's Business Daily)
-32.98%
06:30AM
Jun-26-25 09:49AM
Jun-25-25 12:15PM
11:05AM
08:56AM
Jun-24-25 09:00AM
Jun-21-25 09:30AM
Jun-20-25 09:25AM
Jun-17-25 09:00AM
Jun-12-25 09:35AM
Jun-11-25 09:25AM
May-21-25 11:22AM
May-14-25 03:15AM
May-13-25 04:19PM
(Associated Press Finance)
04:05PM
09:00AM
May-12-25 09:37AM
May-06-25 09:15AM
May-05-25 08:00AM
Apr-21-25 05:02PM
(GuruFocus.com)
+5.96%
+16.53%
08:00AM
Apr-01-25 09:00AM
Mar-21-25 06:23PM
Mar-20-25 04:41PM
10:21AM
(Thomson Reuters StreetEvents)
Mar-19-25 06:57PM
06:56PM
05:15PM
04:17PM
(Associated Press Finance)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy ("DMD"), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
M.D. Dr. Frank Isaac Litvack FACC
Co-Founder Dr. Linda Marban Ph.D.
CFO & Corporate Treasurer Mr. Anthony J. Bergmann M.B.A.
J.D. Ms. Karen G. Krasney Esq.
Chief Operating & Science Officer Dr. Kristi A. H. Elliott Ph.D.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bergmann Anthony CHIEF FINANCIAL OFFICER May 18 '26 Option Exercise 1.39 3,000 4,170 11,223 May 19 04:15 PM Musket David B Director May 19 '26 Proposed Sale 27.00 88,788 2,397,256 May 19 11:40 AM Litvack Frank Director May 13 '26 Option Exercise 1.39 3,937 5,472 133,776 May 14 05:00 PM Krasney Karen EVP, GENERAL COUNSEL May 01 '26 Option Exercise 3.18 25,000 79,500 55,547 May 04 04:30 PM Krasney Karen EVP, GENERAL COUNSEL May 01 '26 Sale 31.70 25,000 792,548 30,547 May 04 04:30 PM Bergmann Anthony CHIEF FINANCIAL OFFICER May 01 '26 Option Exercise 3.18 25,000 79,500 33,223 May 04 04:30 PM Bergmann Anthony CHIEF FINANCIAL OFFICER May 01 '26 Sale 31.70 25,000 792,540 8,223 May 04 04:30 PM Sabar Karimah Es Director Apr 02 '26 Option Exercise 3.18 7,529 23,942 7,529 Apr 03 05:00 PM Sabar Karimah Es Director Apr 02 '26 Sale 32.00 7,529 240,928 0 Apr 03 05:00 PM Karimah Es Sabar Director Apr 02 '26 Proposed Sale 30.12 7,529 226,773 Apr 02 04:24 PM Krasney Karen EVP, GENERAL COUNSEL Mar 31 '26 Option Exercise 3.61 25,000 90,293 55,547 Apr 01 08:00 PM Krasney Karen EVP, GENERAL COUNSEL Mar 31 '26 Sale 30.12 25,000 752,935 30,547 Apr 01 08:00 PM Sabar Karimah Es Director Mar 31 '26 Option Exercise 4.86 61,265 297,748 61,265 Apr 01 08:00 PM Sabar Karimah Es Director Apr 01 '26 Option Exercise 4.86 53,735 261,152 53,735 Apr 01 08:00 PM Sabar Karimah Es Director Mar 31 '26 Sale 30.17 61,265 1,848,243 0 Apr 01 08:00 PM Sabar Karimah Es Director Apr 01 '26 Sale 31.03 53,735 1,667,225 0 Apr 01 08:00 PM Bergmann Anthony CHIEF FINANCIAL OFFICER Mar 31 '26 Option Exercise 3.18 25,000 79,500 33,223 Apr 01 08:00 PM Bergmann Anthony CHIEF FINANCIAL OFFICER Mar 31 '26 Sale 30.13 25,000 753,152 8,223 Apr 01 08:00 PM Karen Krasney Officer Mar 31 '26 Proposed Sale 27.77 75,000 2,082,750 Mar 31 04:23 PM ANTHONY BERGMANN Officer Mar 31 '26 Proposed Sale 27.77 75,000 2,082,750 Mar 31 04:23 PM Karimah Es Sabar Director Mar 31 '26 Proposed Sale 27.77 115,000 3,193,550 Mar 31 04:22 PM Krasney Karen EVP, GENERAL COUNSEL Dec 30 '25 Option Exercise 1.39 2,500 3,475 30,547 Mar 27 07:15 PM DUNBAR GEORGE W JR Director Dec 19 '25 Option Exercise 1.39 3,000 4,170 14,306 Dec 23 02:55 PM
